249 filings
Page 8 of 13
8-K
hxe 9mu7pbifknklejxe
20 May 13
Submission of Matters to a Vote of Security Holders
12:00am
8-K
9zlga3zu
2 May 13
Threshold Pharmaceuticals Reports First Quarter 2013 Financial and Operational Results
12:00am
8-K
zemwchpv6g7oz
15 Mar 13
Departure of Directors or Certain Officers
12:00am
8-K
ykwg4o99s
7 Mar 13
Threshold Pharmaceuticals Reports Fourth Quarter and Year End 2012 Financial and Operational Results
12:00am
8-K
i8pbg5ilz1w9lau
25 Jan 13
Other Events
12:00am
8-K
ky9cq1nzvsx0teij4 yn
15 Nov 12
Other Events
12:00am
8-K
iax9e xfdptrcy5
2 Nov 12
Threshold Pharmaceuticals Reports Third Quarter 2012 Financial and Operational Results
12:00am
8-K
xnj n3uw5w
16 Oct 12
Other Events
12:00am
8-K
nldedb1u
2 Oct 12
Other Events
12:00am
8-K
x4fl svokwd75
17 Sep 12
Threshold Pharmaceuticals to Present Updated Data from Phase 2b
12:00am
8-K
hii9r
2 Aug 12
Threshold Pharmaceuticals Reports SECONd Quarter 2012 Financial AND OPERATIONAL Results
12:00am
8-K
h3tgnqw5cx2
5 Jun 12
Threshold Pharmaceuticals Announces Highlights of TH-302 Presentations at 2012 American Society of Clinical Oncology Annual Meeting
12:00am
8-K
x0eyjp
18 May 12
Submission of Matters to a Vote of Security Holders
12:00am
8-K
k3dcw2mfxzmjqmdr
4 May 12
Threshold Pharmaceuticals Reports FIRST Quarter 2012 Financial AND OPERATIONAL Results
12:00am
8-K
pqcp6rcj677kndwahl
12 Apr 12
Entry into a Material Definitive Agreement
12:00am
8-K
397up7bd
12 Apr 12
Threshold Pharmaceuticals Earns $20 million Milestone Payment from Merck KGaA for Positive Results from Phase 2 Trial of TH-302 in Pancreatic Cancer
12:00am
8-K
wv2vx
30 Mar 12
Other Events
12:00am
8-K
7l4v14if8ww7
19 Mar 12
Threshold Pharmaceuticals' TH-302 Receives Orphan Drug Designation in the European Union for the Treatment of Soft Tissue Sarcoma
12:00am
8-K
q9rhofgx0l4idcfh
14 Mar 12
Other Events
12:00am
8-K
ezgh3de2m af
8 Mar 12
Threshold Pharmaceuticals Reports Fourth Quarter and Year end 2011 Financial AND OPERATIONAL Results
12:00am